Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study

BACKGROUND: Anti-programmed cell death ligand 1/vascular endothelial growth factor inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit, but it has not been investigated in advanced biliary tract cancer (BTC). OBJECTIVES: We investigated the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kang, Liu, Zong-Han, Yu, Hong-Ming, Cheng, Yu-Qiang, Xiang, Yan-Jun, Zhong, Jing-Ya, Ni, Qian-Zhi, Zhou, Li-Ping, Liang, Chao, Zhou, Hong-Kun, Pan, Wei-Wei, Guo, Wei-Xing, Shi, Jie, Cheng, Shu-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052479/
https://www.ncbi.nlm.nih.gov/pubmed/37007215
http://dx.doi.org/10.1177/17562848231160630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052479/
https://www.ncbi.nlm.nih.gov/pubmed/37007215
http://dx.doi.org/10.1177/17562848231160630

Ejemplares similares